logo
Community Health Systems to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Community Health Systems to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Business Wire14-05-2025
FRANKLIN, Tenn.--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the 2025 RBC Capital Markets Global Healthcare Conference to be held May 20-21, 2025, in New York.
The Company will host a fireside chat presentation on Wednesday, May 21, 2025, at 2:05 p.m. ET, 1:05 p.m. CT. The fireside chat presentation will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company's website, www.chs.net, and a replay will be available using that same link.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation's largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 36 distinct markets across 14 states. As of April 23, 2025, the Company's subsidiaries own or lease 71 affiliated hospitals with more than 10,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The Company's headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol 'CYH.' More information about the Company can be found on its website at www.chs.net.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coherent Eyes Core Growth Markets Following Defense Unit Sale
Coherent Eyes Core Growth Markets Following Defense Unit Sale

Yahoo

time21 minutes ago

  • Yahoo

Coherent Eyes Core Growth Markets Following Defense Unit Sale

On Wednesday, Coherent Corp. (NYSE:COHR) agreed to sell its Aerospace and Defense business to Advent, a private equity investor, for $400 million. Proceeds will be used to reduce debt and will be immediately accretive to Coherent's EPS. Coherent's Aerospace and Defense designs and manufactures optical and laser systems for defense applications. The business includes approximately 550 employees and 10 geographic sites.'We are pleased to have reached this agreement with Advent. As part of our strategic portfolio optimization process, this transaction furthers our strategy to concentrate efforts on core growth markets and products,' said Jim Anderson, CEO of Coherent. The deal is expected to close in the current quarter. During the earnings call, Anderson said the decision to sell the business was made because it was not aligned with the company's long-term strategic focus areas and did not support long-term financial targets. View more earnings on COHR Coherent reported quarterly earnings of $1 per share, which beat the analyst consensus estimate of 91 cents. Revenue came in at $1.52 billion, which beat the analyst consensus estimate of $1.5 billion and is up from revenue of $1.31 billion from the same period last year. Outlook Coherent expects first-quarter revenue to be between $1.46 billion and $1.6 billion. On the earnings call, CEO Anderson said the current tariff policy remains unchanged from last quarter and is not expected to have a significant impact this quarter. 'Though we do not have full details yet, we believe President Trump's recent announcement regarding semiconductor tariffs may present a competitive advantage for our business,' Anderson noted. The semiconductor exemption covers many of the company's products, such as transceivers, and with U.S. manufacturing operations, the company expects it could avoid the semiconductor tariff. Analysts' Reaction Bank of America Securities downgraded Coherent from Buy to Neutral while raising its price forecast from $92 to $105. Needham reiterated its Buy rating with a $120 forecast, while Stifel also maintained a Buy but lifted its forecast from $100 to $118. Rosenblatt kept a Buy rating but trimmed its forecast from $150 to $135. Barclays maintained an Overweight stance and raised its forecast from $90 to $110. Price Action: COHR stock is trading lower by 23.47% to $87.25 at last check Thursday. Read Next:Image via Shutterstock Latest Ratings for COHR Date Firm Action From To Oct 2021 Stifel Reinstates Hold Sep 2021 Susquehanna Downgrades Positive Neutral Feb 2021 Benchmark Downgrades Buy Hold View More Analyst Ratings for COHR View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? COHERENT (COHR): Free Stock Analysis Report This article Coherent Eyes Core Growth Markets Following Defense Unit Sale originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations

Business Wire

time22 minutes ago

  • Business Wire

Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Philips, a global leader in health technology, today announced a plan for new investments of more than USD 150 million in U.S. manufacturing and research and development (R&D). As part of today's announcement, Philips unveiled the expansion of its Reedsville, PA, manufacturing facility, which produces AI-enabled ultrasound systems for hospitals across the U.S. These investments come on top of Philips' annual USD 900 million R&D investment in the U.S. as well as investments in nearly 17,000 colleagues across 40 facilities in the United States. Philips has employees in every U.S. state supporting innovations used by clinicians and patients in 90% of hospitals across the country. The investment announced today by Philips includes the expansion of its Reedsville, PA, site and the recently announced expansion of Philips' Image Guided Therapy facility in Plymouth, MN. It also includes additional manufacturing and R&D projects which will come over the next several years to support the company's growth in the U.S. The Reedsville site, which currently manufactures transducers, will also customize the software and configurations of ultrasound systems for specific clinical procedures in cardiovascular, general and maternal care following the expansion. As an example, Philips' industry-leading CV ultrasound platform delivers advanced tools to help doctors diagnose structural heart and coronary artery disease quickly and confidently [1]. 'The proposed planned expansion of our manufacturing facilities is a demonstration of our deep commitment to the U.S. region,' said Jeff DiLullo, Chief Region Leader, Philips North America. 'Each year, Philips spends $900 million in R&D in the U.S. to drive innovation and deliver cutting-edge technology that empowers healthcare professionals to diagnose, treat and monitor patients more effectively. Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The expansion of the Reedsville site is expected to add 24,000 square feet of manufacturing space in addition to 40,000 square feet of warehouse space and is expected to create 120 skilled manufacturing jobs. The recently announced expansion of Philips' image-guided therapy facility in Plymouth, MN, which includes the construction of a new medtech training center, is expected to create over 150 new jobs. [1] Philips ultrasound: The next dimension in echocardiography About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statements and other important information This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Deadline Alert: SelectQuote, Inc. (SLQT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Deadline Alert: SelectQuote, Inc. (SLQT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Business Wire

time22 minutes ago

  • Business Wire

Deadline Alert: SelectQuote, Inc. (SLQT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired SelectQuote, Inc. ('SelectQuote' or the 'Company') (NYSE: SLQT) securities between September 9, 2020 and May 1, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR SELECTQUOTE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 1, 2025, the U.S. Department of Justice ('DOJ') filed a False Claims Act complaint against SelectQuote, alleging, '[f]rom 2016 through at least 2021' SelectQuote received 'tens of millions of dollars' in 'illegal kickbacks' from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers 'unbiased coverage comparisons' when in fact it 'repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans.' On this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provide unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased or otherwise acquired SelectQuote securities during the Class Period, you may move the Court no later than October 10, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store